Myelodysplastic Syndrome Treatment Market

Myelodysplastic Syndrome Treatment Market Outlook (2022 to 2032)

The global myelodysplastic syndrome treatment market is poised to register a 5.9% CAGR, capturing a revenue share of USD 2,990.8 million in 2022, to reach USD 5,614.1 million by 2032.

Report Attribute	Details
Myelodysplastic Syndrome Treatment Market Value (2022)	USD 2,990.8 Million
Myelodysplastic Syndrome Treatment Market Anticipated Forecast Value (2032)	USD 5,614.1 Million
Myelodysplastic Syndrome Treatment Market Projected Growth Rate (2022 to 2032)	5.9%

The rising adoption of myelodysplastic syndrome treatment can be attributed to new drugs and drug combinations that may work better and have less severe side effects that are the subject of studies.

Currently, the myelodysplastic syndrome treatment market trends are shaped by some of the most effective medications for treating MDS, classified as hypomethylating agents, such as azacitidine (Vidaza) and decitabine (Dacogen).

In the USA, myelodysplastic syndromes (MDS) occur at a rate of 4.8 cases for every 100,000 people, positively impacting the myelodysplastic syndrome treatment adoption trends.

In addition to this, the adoption of myelodysplastic syndrome treatment is on the surge as the number of new cases diagnosed each year seems to be increasing as the average age of the population increases. (Source: American Cancer Society).

Furthermore, diagnosis techniques such as blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS, leading to the demand for myelodysplastic syndrome treatment.

What are the Key Myelodysplastic Syndrome Treatment Market Dynamics?

The myelodysplastic syndrome treatment market size is expected to expand to a significant extent in the coming few years due to increasing mutation in treatments, which cause myelodysplastic syndrome.

Moreover, growing number of patient pool of age 50 and above, and rising government support for cancer treatment augurs well for the myelodysplastic syndrome treatment market future trends.

However, unawareness about such treatments is one of the major factors mitigating the demand for myelodysplastic syndrome treatment.

The complexity and clonal heterogeneity of MDS also pose a challenge to the myelodysplastic syndrome treatment growth as it is frequently unknown, which mutations are early initiating events and are later events that only affect a subclone.

Despite these concerns, researchers are currently testing a number of strategies to try to enhance existing MDS therapeutics, in turn, create numerous myelodysplastic syndrome treatment market opportunities.

One of such myelodysplastic syndrome treatment market trends is the combination therapies that have either additive or synergistic effects in vitro.

Higher response rates than those seen with either drug alone may be possible when azacitidine is combined with lenalidomide or vorinostat (a deacetylase inhibitor currently FDA approved for treating cutaneous T-cell lymphoma).

The myelodysplastic syndrome treatment market outlook is to be swayed by a cooperative group trial in the United States and Canada that are currently investigating whether these combinations will improve patient outcomes in comparison to azacitidine monotherapy.

How is the North America Myelodysplastic Syndrome Treatment Market Evolving?

Due to the rising healthcare costs, and rising end-user demand for myelodysplastic syndrome treatment, North America is anticipated to control a myelodysplastic syndrome treatment market share of 34.6% in 2022.

And as the growth is further fostered by the focus of major players and non-profit organisations present on launching new initiatives and public awareness campaigns to inform people about gout disease and support medical professionals.

A growing awareness of MDS among Americans is expected to cause the USA to expand the myelodysplastic syndrome treatment market size over the forecast period.

What is the Growth Outlook for the Europe Myelodysplastic Syndrome Treatment Market?

Europe is predicted to experience significant growth and hold a market share of 31.1% in 2022 due to an increase in governmental initiatives for disease diagnosis and treatment.

As an illustration, the European LeukemiaNet WP8 promoted a programme with the goal of creating and regularly updating evidence- and consensus-based guidelines to provide clinical practise recommendations for standardised diagnostic and prognostic procedures and for an appropriate choice of therapeutic interventions in adult patients with primary MDS.

A significant factor that is anticipated to propel the myelodysplastic syndrome treatment market share of Europe is the increasing efforts made by pharmaceutical companies to introduce highly effective therapies for MDS.

How is the Start-up Ecosystem in the Myelodysplastic Syndrome Treatment Market?

The oral medication tamibarotene from Syros Pharmaceuticals has been given orphan drug designation (ODD) by the USA Food and Drug Administration (FDA) to treat myelodysplastic syndrome (MDS).

A selective retinoic acid receptor alpha (RAR) agonist is tamibarotene.

In the Phase III SELECT-MDS-1 clinical trial, oral therapy is currently being evaluated in addition to azacitidine to treat RARA-positive patients with recently discovered higher-risk MDS (HR-MDS).

The effectiveness and safety of the combination therapy are being evaluated in this ongoing trial.

The pivotal trial's results are expected by the company in the fourth quarter of 2019 or the first quarter of 2024.

In 2024, Syros also intends to submit a potential new drug application.

How is the Competition Landscape in the Myelodysplastic Syndrome Treatment Market?

The myelodysplastic syndrome treatment market is consolidated with a presence of few strong players from around the globe.

Some of the players identified in global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Holdings Co., Ltd., Sandoz, Inc., Dr. Reddy's Laboratories, Inc., Accord Healthcare Ltd., Mylan N.V., Pfizer, Inc. etc.

Emerging trends in myelodysplastic syndrome treatment market are brought about as a result of the major players' adoption of several growth strategies, including product launches, acquisitions, and collaborations.

Some of the recent developments in the myelodysplastic syndrome treatment market are as follows:

• Pevonedistat, an investigational drug from Takeda Pharmaceutical Company, has received FDA Breakthrough Therapy Designation for the treatment of patients with higher-risk myelodysplastic syndromes.
• Gilead Sciences, Inc. and Forty-Seven, Inc. have entered into a definitive agreement under which Gilead will acquire Forty-Seven for USD 95.50 per share in cash. Magrolimab, Forty Seven's investigational lead product candidate.

Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL).

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 5.9% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2014 to 2020
Forecast Period	2022 to 2032
Quantitative Units	Revenue in USD Million and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Type, Treatment, Patient Group, Region
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; Asia Pacific excluding Japan; Japan; The Middle East and Africa
Key Countries Profiled	USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa
Key Companies Profiled	Celgene Corporation; Otsuka Holdings Co., Ltd.; Sandoz, Inc.; Dr. Reddy's Laboratories, Inc.; Accord Healthcare Ltd.; Mylan N.V.; Pfizer, Inc.
Customization	Available Upon Request

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
• 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type
  • 5.1. Refractory cytopenia with unilineage dysplasia (RCUD)
  • 5.2. Refractory anemia with ringed sideroblasts (RARS)
  • 5.3. Refractory cytopenia with multilineage dysplasia (RCMD)
  • 5.4. Refractory anemia with excess blasts to 1 (RAEB to 1)
  • 5.5. Refractory anemia with excess blasts to 2 (RAEB to 2)
  • 5.6. Myelodysplastic syndrome, unclassified (MDS to U)
  • 5.7. Myelodysplastic syndrome associated with isolated del(5q)
• 6. Global Market 2017 to 2021 and Forecast 2022 to 2032, By Treatment
  • 6.1. Chemotherapy
  • 6.2. Immunotherapy
  • 6.3. Stem cell transplantation / bone marrow transplantation
  • 6.4. Growth Factors
• 7. Global Market 2017 to 2021 and Forecast 2022 to 2032, By Patient Group
  • 7.1. Above 50 years
  • 7.2. Below 50 years
• 8. Global Market 2017 to 2021 and Forecast 2022 to 2032, By Region
  • 8.1. North America
  • 8.2. Latin America
  • 8.3. Europe
  • 8.4. Asia Pacific
  • 8.5. MEA
• 9. North America Market 2017 to 2021 and Forecast 2022 to 2032, By Country
• 10. Latin America Market 2017 to 2021 and Forecast 2022 to 2032, By Country
• 11. Europe Market 2017 to 2021 and Forecast 2022 to 2032, By Country
• 12. Asia Pacific Market 2017 to 2021 and Forecast 2022 to 2032, By Country
• 13. MEA Market 2017 to 2021 and Forecast 2022 to 2032, By Country
• 14. Key Countries Market
• 15. Market Structure Analysis
• 16. Competition Analysis
  • 16.1. Celgene Corporation
  • 16.2. Otsuka Holdings Co., Ltd
  • 16.3. Sandoz, Inc.
  • 16.4. Dr. Reddy's Laboratories, Inc.
  • 16.5. Accord Healthcare Ltd.
  • 16.6. Mylan N.V.
  • 16.7. Pfizer, Inc.
• 17. Assumptions & Acronyms Used
• 18. Research Methodology